Filing Details
- Accession Number:
- 0001567619-19-022077
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-11-22 16:09:10
- Reporting Period:
- 2019-11-20
- Accepted Time:
- 2019-11-22 16:09:10
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1512762 | Coherus Biosciences Inc. | CHRS | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1427569 | Jean-Frederic Viret | Coherus Biosciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City CA 94065 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 Par Value | Acquisiton | 2019-11-20 | 3,159 | $10.05 | 6,462 | No | 4 | M | Direct | |
| Common Stock, $0.0001 Par Value | Disposition | 2019-11-20 | 3,159 | $19.59 | 3,303 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-11-20 | 3,159 | $0.00 | 3,159 | $10.05 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 111,046 | 2028-02-01 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person.
- The transaction was executed in multiple trades in prices ranging from $19.085 to $19.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Billionaire Hedge Funds
